First-in-Human Drug Dosing: How Could FDA Models Improve

What is the FDA proposing for first-in-human drug dosing?

Within its broader clinical-development initiative, the FDA highlights starting-dose selection as a challenge for therapies with complex mechanisms. Its proposal focuses on quantitative systems pharmacology, or QSP, which combines mathematical modeling with knowledge of disease biology and drug action. The agency presents this as a tool to support decisions before a medicine is first administered to people. [FDA clinical-development announcement](https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development).

The June draft addresses medicines for which a minimum anticipated biological effect level, known as MABEL, is an appropriate starting point. This means estimating a dose expected to produce a small biological response. Potential applications include drugs that activate T cells and trigger cytokine release. The document remains draft guidance, rather than an approval of any treatment. [FDA QSP draft guidance](https://www.fda.gov/media/193230/download).

Why can experimental medicines need more than animal-based dose calculations?

The FDA's established guidance for initial trials in healthy adults describes converting an animal dose without observed adverse effects into a human-equivalent dose, then applying a safety factor. It also recognizes limitations: humans may be more sensitive, drug exposure may differ between species, and some adverse effects can be difficult to detect in animals. These uncertainties influence how cautiously researchers select the first dose. [FDA starting-dose guidance](https://www.fda.gov/files/drugs/published/Estimating-the-Maximum-Safe-Starting-Dose-in-Initial-Clinical-Trials-for-Therapeutics-in-Adult-Healthy-Volunteers.pdf).

QSP can incorporate human-cell experiments, target-binding measurements and other relevant evidence to simulate a medicine's effects. The draft emphasizes checking model reliability and examining how uncertain assumptions change the predicted dose. For novel targets without clinical precedent, it recommends choosing the lowest starting-dose estimate when models and traditional methods disagree. [FDA QSP draft guidance](https://www.fda.gov/media/193230/download).

How should early drug trials protect participants as doses increase?

European Medicines Agency guidance describes sentinel dosing: giving the investigational medicine to one participant before exposing the rest of a group, with an appropriate observation period and review. Researchers should also assess available safety and drug-exposure data before moving to subsequent groups. These precautions help identify emerging problems while limiting simultaneous exposure. [EMA early-trial safety guideline](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf).

The same guideline calls for clear rules governing when dosing must stop and a plan for identifying and managing adverse reactions. For prospective participants, a practical implication is to ask how the initial dose was justified, what observations permit an increase and what findings would trigger a pause. These questions help explain how the study manages uncertainty. [EMA early-trial safety guideline](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf).